SpringWorks Therapeutics, Inc. (SWTX)

Market Cap	1.92B
Revenue (ttm)	n/a
Net Income (ttm)	-259.31M
Shares Out	62.38M
EPS (ttm)	-5.20
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	502,885
Open	29.94
Previous Close	30.07
Day's Range	29.94 - 31.27
52-Week Range	13.60 - 65.92
Beta	0.57
Analysts	Buy
Price Target	65.79 (+113.54%)
Earnings Date	Feb 23, 2023

About SWTX

SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas, as well as Phase 1/2a clini...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Mr. Saqib Islam J.D.
• Employees: 222
• Stock Exchange: NASDAQ
• Ticker Symbol: SWTX

Analyst Forecast

According to 13 analysts, the average rating for SWTX stock is "Buy." The 12-month stock price forecast is $65.79, which is an increase of 113.54% from the latest price.

Price Target

$65.79

(113.54% upside)

Analyst Consensus: Buy